Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
SYK Stock News and Mentions of Stryker Corp. Stocktwits
Updated: April 28, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Stryker Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Stryker Corp. (SYK).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Stryker stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Stryker Corp. (SYK)
April 25, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
Analysts Estimate Agios Pharmaceuticals ( AGIO ) to Report a Decline in Earnings: What to Look Out for
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 25, 2024 (13:15) / "Zacks Commentary" (by Zacks Equity Research)
Seeking Clues to Stryker ( SYK ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Stryker (SYK) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
In Article Trend: Neutral
April 24, 2024 (16:44) / "Zacks Commentary" (by Urmimala Biswas)
SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?
SYK and ZBH are expected to have witnessed strong procedural volume growth across the global market in the first quarter.
In Article Trend: Somewhat-Bullish
April 24, 2024 (12:30) / "CNBC" (by Dave Sheaff Gilreath)
Op-ed: Here are 6 health-care stocks to watch now, amid a bumpy recovery
Health care, long an ailing stock market sector, has recovered over the past six months, with currently robust vital signs and strong growth projections.
In Article Trend: Somewhat-Bullish
April 24, 2024 (10:25) / "Zacks Commentary" (by Zacks Equity Research)
Ongoing Procedural Growth May Aid Stryker's ( SYK ) Q1 Earnings
Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
In Article Trend: Somewhat-Bullish
April 23, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Stryker ( SYK ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 19, 2024 (22:12) / "PR Newswire"
Endoscopy Devices Market size is set to grow by USD 14.24 billion from 2024-2028, advances in endoscopy ... - PR Newswire
Endoscopy Devices Market size is set to grow by USD 14.24 billion from 2024-2028, advances in endoscopy ... PR ...
In Article Trend: Somewhat-Bullish
April 19, 2024 (19:45) / "Benzinga" (by Benzinga Insights)
Stryker Unusual Options Activity For April 19 - Stryker ( NYSE:SYK )
Financial giants have made a conspicuous bearish move on Stryker. Our analysis of options history for Stryker SYK revealed 8 unusual trades. Delving into the details, we found 25% of traders were bullish, while 75% showed bearish tendencies.
In Article Trend: Neutral
April 18, 2024 (15:09) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Medtronic ( MDT ) Stock for Now
Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.
In Article Trend: Somewhat-Bullish
April 17, 2024 (19:30) / "Benzinga" (by Benzinga Insights)
Here's How Much You Would Have Made Owning Stryker Stock In The Last 20 Years - Stryker ( NYSE:SYK )
Stryker SYK has outperformed the market over the past 20 years by 2.32% on an annualized basis producing an average annual return of 9.99%. Currently, Stryker has a market capitalization of $128.55 billion.
In Article Trend: Somewhat-Bullish
April 17, 2024 (15:07) / "Zacks Commentary" (by Zacks Equity Research)
Henry Schein ( HSIC ) Global Presence Aids, Macroeconomic Woes Stay
Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.
In Article Trend: Somewhat-Bullish
April 17, 2024 (14:26) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Chemed ( CHE ) Stock for Now
Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.
In Article Trend: Somewhat-Bullish
April 16, 2024 (15:50) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Charles River ( CRL ) Stock Now
Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.
In Article Trend: Somewhat-Bullish
April 16, 2024 (14:56) / "Zacks Commentary" (by Zacks Equity Research)
Bio-Rad ( BIO ) Hurt by Softness in BioPharma and Competition
Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.
In Article Trend: Neutral
April 12, 2024 (14:45) / "Zacks Commentary" (by Zacks Equity Research)
Hologic's ( HOLX ) New Launches Aid, Macroeconomic Issues Ail
Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.
In Article Trend: Neutral
April 12, 2024 (13:03) / "Zacks Commentary" (by Zacks Equity Research)
Why You Should Add Haemonetics ( HAE ) to Your Portfolio Now
Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).
In Article Trend: Somewhat-Bullish
April 11, 2024 (13:15) / "Zacks Commentary" (by Zacks Equity Research)
Smith+Nephew ( SNN ) Expands in Australia With New Alliance
The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.
In Article Trend: Bullish
April 11, 2024 (10:45) / "Benzinga" (by Zacks)
Boston Scientific ( BSX ) Faces Rising Costs, Competition - Boston Scientific ( NYSE:BSX ) , Cardinal Health ( NYSE:CAH )
Boston Scientific Corporation BSX has been struggling due to unfavorable currency movement and macroeconomic woes. Strong competitors in the large medical device market also pose a tough challenge for Boston Scientific. The stock carries a Zacks Rank #4 ( Sell ) currently.
In Article Trend: Neutral
April 10, 2024 (15:10) / "Zacks Commentary" (by Zacks Equity Research)
Align Technology ( ALGN ) Up 20.5% YTD: Will the Rally Continue?
Investors are optimistic about Align Technology (ALGN) driven by geographic expansion and upbeat guidance.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) Faces Rising Costs, Competition
With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.
In Article Trend: Neutral
April 9, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Myriad Genetics ( MYGN ) Stock Now
Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
In Article Trend: Somewhat-Bullish
April 9, 2024 (13:03) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp's ( LH ) Strategic Alliances Aid Amid Macroeconomic Woes
Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.
In Article Trend: Somewhat-Bullish
April 9, 2024 (13:02) / "Zacks Commentary" (by Zacks Equity Research)
Bruker ( BRKR ) Introduces Magnet Technology for NMR Adoption
Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.
In Article Trend: Somewhat-Bullish
April 9, 2024 (12:41) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Integra ( IART ) Stock Now
Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.
In Article Trend: Somewhat-Bullish
April 9, 2024 (12:34) / "Zacks Commentary" (by Zacks Equity Research)
Thermo Fisher ( TMO ) Launches TSX Universal Series ULT Freezers
Thermo Fisher's (TMO) new ENERGY STAR-certified TSX Universal Series ULT Freezers deliver tighter temperature control and faster recovery times.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) Faces Low Testing Demand, Currency Headwinds
Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
IM Cannabis ( IMCC ) Expands Business in Germany With New Alliance
The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
In Article Trend: Bullish
April 8, 2024 (13:35) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Penumbra ( PEN ) Stock for Now
Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:34) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp ( LH ) Extends MRD Clinical Research With New Launch
Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.
In Article Trend: Neutral
April 8, 2024 (12:18) / "Zacks Commentary" (by Zacks Equity Research)
Teleflex ( TFX ) Debuts the New Unified UroLift 2 System With ATC
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
In Article Trend: Somewhat-Bullish
April 5, 2024 (13:52) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) Receives FDA's Approval for the TriClip TEER System
Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
In Article Trend: Somewhat-Bullish
April 5, 2024 (13:48) / "Zacks Commentary" (by Zacks Equity Research)
Haemonetics' ( HAE ) New TEG 6s Cartridge Gets FDA Approval
Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.
In Article Trend: Somewhat-Bullish
April 5, 2024 (11:17) / "Zacks Commentary" (by Zacks Equity Research)
Henry Schein ( HSIC ) Buys TriMed to Expand in Orthopedic Space
According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.
In Article Trend: Somewhat-Bullish
April 4, 2024 (17:29) / "Benzinga" (by Zacks)
Globus Medical ( GMED ) Gains From New Launches Amid Macro Issues - DaVita ( NYSE:DVA ) , Cardinal Health ( NYSE:CAH )
Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company is expanding in the overseas markets through the expansion of direct and distributor sales force.
In Article Trend: Somewhat-Bullish
April 4, 2024 (17:22) / "Zacks Commentary" (by Zacks Equity Research)
QIAGEN ( QGEN ) Boosts Cancer Research Suite With New Launches
QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.
In Article Trend: Neutral
April 4, 2024 (15:59) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add Cardinal Health ( CAH ) to Your Portfolio Now
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
In Article Trend: Somewhat-Bullish
April 4, 2024 (12:41) / "Zacks Commentary" (by Zacks Equity Research)
Globus Medical ( GMED ) Gains From New Launches Amid Macro Issues
Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
In Article Trend: Somewhat-Bullish
April 4, 2024 (12:24) / "Zacks Commentary" (by Zacks Equity Research)
Align ( ALGN ) Debuts Invisalign Palatal Expander in New Markets
Align's (ALGN) Invisalign Palatal Expander system is now available in Australia and New Zealand for skeletal and dental expansion in growing patients.
In Article Trend: Somewhat-Bullish
April 3, 2024 (15:22) / "Zacks Commentary" (by Zacks Equity Research)
Quest Diagnostics ( DGX ) Collaborates With Broad Clinical Labs
Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
In Article Trend: Neutral
April 3, 2024 (13:57) / "Zacks Commentary" (by Zacks Equity Research)
Exact Sciences' ( EXAS ) Oncoguard Esophagus Test Looks Promising
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.
In Article Trend: Neutral
April 3, 2024 (13:51) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Buy Alcon ( ALC ) Stock Right Now
Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).
In Article Trend: Somewhat-Bullish
April 2, 2024 (15:20) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Labcorp ( LH ) Stock for Now
Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.
In Article Trend: Somewhat-Bullish
April 2, 2024 (15:18) / "Zacks Commentary" (by Zacks Equity Research)
Abbott's ( ABT ) i-STAT TBI Cartridge Receives FDA Approval
Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.
In Article Trend: Neutral
April 2, 2024 (13:06) / "Zacks Commentary" (by Zacks Equity Research)
Prestige Consumer ( PBH ) Banks on its Portfolio Amid Cost Woes
Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.
In Article Trend: Somewhat-Bullish
April 2, 2024 (12:36) / "Zacks Commentary" (by Zacks Equity Research)
Thermo Fisher ( TMO ) Debuts a New In-Line Metrology Solution
Thermo Fisher's (TMO) new LInspector Edge In-line Mass Profilometer delivers real-time, full-coverage mass loading analysis for battery electrode coating.
In Article Trend: Somewhat-Bullish
April 2, 2024 (12:35) / "Zacks Commentary" (by Indrajit Bandyopadhyay)
5 Medical Product Stocks to Buy Amid Industry Challenges
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.
In Article Trend: Somewhat-Bullish
April 2, 2024 (12:31) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Invest in IDEXX ( IDXX ) Stock Right Now
The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).
In Article Trend: Somewhat-Bullish
April 1, 2024 (16:44) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Buy ResMed ( RMD ) Stock Now
Investors are optimistic about ResMed (RMD) led by the strong uptake of the myAir app with Air 11 systems.
In Article Trend: Somewhat-Bullish
April 1, 2024 (16:42) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp ( LH ) to Boost Clinical Diagnostics With New Deal
The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:41) / "Zacks Commentary" (by Zacks Equity Research)
Tandem Diabetes ( TNDM ) Gains From Innovation Amid Macro Issues
Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:32) / "Zacks Commentary" (by Zacks Equity Research)
Paragon 28 ( FNA ) Expands Syndesmotic Repair Line With New Launch
The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.
In Article Trend: Somewhat-Bullish
April 1, 2024 (12:15) / "Zacks Commentary" (by Zacks Equity Research)
Medtronic's ( MDT ) Newest Evolut TAVR System Gets FDA Approval
Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.
In Article Trend: Somewhat-Bullish
March 29, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Is Stryker ( SYK ) Stock Outpacing Its Medical Peers This Year?
Here is how Stryker (SYK) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.
In Article Trend: Somewhat-Bullish
March 28, 2024 (15:34) / "Zacks Commentary" (by Zacks Equity Research)
Walgreens Boots ( WBA ) Q2 Earnings Top Estimates, EPS View Down
Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal second quarter benefited from higher branded drug inflation and strong execution in pharmacy services.
In Article Trend: Neutral
March 28, 2024 (15:17) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain STERIS ( STE ) Stock for Now
Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.
In Article Trend: Somewhat-Bullish
March 28, 2024 (14:04) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add Lantheus ( LNTH ) to Your Portfolio
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 28, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
Shockwave Medical ( SWAV ) Up on Potential Acquisition Rumors
Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:03) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) and Scivita Medical Expand Partnership
Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:01) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Thermo Fisher ( TMO ) Stock
Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).
In Article Trend: Somewhat-Bullish
March 27, 2024 (17:00) / "Benzinga" (by Benzinga Insights)
Price Over Earnings Overview: Stryker - Stryker ( NYSE:SYK )
In the current session, the stock is trading at $351.79, after a 0.63% spike. Over the past month, Stryker Inc. SYK stock increased by 1.24%, and in the past year, by 26.87%.
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:30) / "Benzinga" (by Benzinga Insights)
Looking Into Stryker's Recent Short Interest - Stryker ( NYSE:SYK )
Stryker's SYK short percent of float has fallen 12.03% since its last report. The company recently reported that it has 4.18 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.32 days to cover their ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:25) / "Zacks Commentary" (by Zacks Equity Research)
Abbott's ( ABT ) Assert-IQ Cardiac Monitor Receives CE Mark
Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:23) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Buy Zimmer Biomet ( ZBH ) Stock Now
Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.
In Article Trend: Somewhat-Bullish
March 27, 2024 (14:54) / "Zacks Commentary" (by Zacks Equity Research)
Stryker's ( SYK ) Latest Launch to Streamline Procedural Workflows
Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.
In Article Trend: Somewhat-Bullish
March 27, 2024 (11:51) / "Zacks Commentary" (by Zacks Equity Research)
Myriad Genetics ( MYGN ) Wins Foundational Patent for MRD Assay
Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.
In Article Trend: Somewhat-Bullish
March 27, 2024 (11:12) / "Zacks Commentary" (by Zacks Equity Research)
Masimo ( MASI ) Plans Consumer Business Spin-Off to Drive Growth
Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.
In Article Trend: Somewhat-Bullish
March 26, 2024 (14:42) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain Intuitive Surgical ( ISRG ) in Your Portfolio
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
In Article Trend: Somewhat-Bullish
March 26, 2024 (14:07) / "Zacks Commentary" (by Zacks Equity Research)
QIAGEN ( QGEN ) Unveils QIAstat-Dx Analyzer With Remote Access
With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.
In Article Trend: Somewhat-Bullish
March 26, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
Charles River ( CRL ) Extends Gene Therapy Deal With NUS Medicine
Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
In Article Trend: Somewhat-Bullish
March 26, 2024 (12:44) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Buy Align Technology ( ALGN ) Stock Now
Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.
In Article Trend: Somewhat-Bullish
March 25, 2024 (19:30) / "Benzinga" (by Benzinga Insights)
$100 Invested In Stryker 20 Years Ago Would Be Worth This Much Today - Stryker ( NYSE:SYK )
Stryker SYK has outperformed the market over the past 20 years by 2.91% on an annualized basis producing an average annual return of 10.81%. Currently, Stryker has a market capitalization of $134.09 billion.
In Article Trend: Somewhat-Bullish
March 22, 2024 (16:24) / "Zacks Commentary" (by Zacks Equity Research)
Tandem Diabetes ( TNDM ) Gains From Innovation Amid Competition
Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.
In Article Trend: Somewhat-Bullish
March 22, 2024 (14:39) / "Zacks Commentary" (by Zacks Equity Research)
Stryker ( SYK ) Acquires SERF SAS to Aid Its Orthopedic Segment
Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.
In Article Trend: Somewhat-Bullish
March 22, 2024 (13:48) / "Zacks Commentary" (by Zacks Equity Research)
Bruker Corporation ( BRKR ) Hits 52-Week High: What's Driving It?
Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.
In Article Trend: Somewhat-Bullish
March 22, 2024 (12:33) / "Zacks Commentary" (by Zacks Equity Research)
Phibro Stock ( PAHC ) Rises 7% YTD: Will the Run Continue?
Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.
In Article Trend: Bullish
March 22, 2024 (10:41) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights Disney, Morgan Stanley, Stryker, Shopify and Delta Air Lines
Disney, Morgan Stanley, Stryker, Shopify and Delta Air Lines are included in this Analyst Blog.
In Article Trend: Somewhat-Bullish
March 21, 2024 (20:42) / "Zacks Commentary" (by Mark Vickery)
Top Stock Reports for Disney, Morgan Stanley & Stryker
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Morgan Stanley (MS) and Stryker Corporation (SYK).
In Article Trend: Somewhat-Bullish
March 21, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add Stryker ( SYK ) Stock in Your Portfolio Now
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
In Article Trend: Bullish
March 21, 2024 (12:10) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain National Vision ( EYE ) Stock Now
The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).
In Article Trend: Somewhat-Bullish
March 21, 2024 (11:15) / "PR Newswire" (by Stryker)
Stryker completes acquisition of SERF SAS
MAHWAH, N.J., USA, March 21, 2024 /PRNewswire/ -- Stryker ( NYSE: SYK ) , a leading global medical technology company, announced today that it has completed the previously announced acquisition of SERF SAS, a France-based joint replacement company, from Menix.
In Article Trend: Somewhat-Bullish
March 20, 2024 (17:23) / "Zacks Commentary" (by Zacks Equity Research)
Walgreens' ( WBA ) AllianceRx Pharmacy Will Distribute VIVJOA
Walgreens' (WBA) specialty pharmacy patients now have exclusive access to 240+ limited distribution drugs.
In Article Trend: Somewhat-Bullish
March 20, 2024 (11:55) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Buy Phibro ( PAHC ) Stock Now
Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.
In Article Trend: Somewhat-Bullish
March 19, 2024 (18:07) / "Zacks Commentary" (by Zacks Equity Research)
Align Technology ( ALGN ) Gains From Innovation, Macro Issues Ail
In terms of innovation, Align Technology successfully launched its first subscription-based clear aligner program Doctor Subscription Program (DSP) worldwide.
In Article Trend: Neutral
March 19, 2024 (17:40) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Abbott ( ABT ) Stock Now
Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.
In Article Trend: Somewhat-Bullish
March 19, 2024 (17:38) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences ( EW ) Up 21.8% YTD: What's Driving It?
Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.
In Article Trend: Bullish
March 19, 2024 (17:09) / "Zacks Commentary" (by Zacks Equity Research)
Inspira Technologies ( IINN ) Strives to Get AMAR Nod for ART100
The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).
In Article Trend: Bullish
March 19, 2024 (15:40) / "Benzinga" (by Globe Newswire)
Cartilage Repair Market Anticipates Rapid Growth, Projected To Reach $2.3 Billion In 2028 As Per The Business Research Company's Cartilage Repair Global Market Report 2024
LONDON, March 19, 2024 ( GLOBE NEWSWIRE ) -- The Business Research Company's Cartilage Repair Market Global Report 2024 forecasts significant growth, with the cartilage repair market size expected to rise from $1.24 billion in 2023 to $1.42 billion in 2024, demonstrating a compound annual growth ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (13:15) / "PR Newswire"
Silvernail Elected International Paper Chief Executive Officer - PR Newswire
Silvernail Elected International Paper Chief Executive Officer PR ...
In Article Trend: Bullish
March 19, 2024 (12:14) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Tandem Diabetes ( TNDM ) Now
Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Chemed ( CHE ) Reaches a New 52-Week High: What's Driving It?
Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:44) / "Zacks Commentary" (by Zacks Investment Research)
Labcorp ( LH ) Presents New Research on Precision Diagnostics
Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
In Article Trend: Neutral
March 18, 2024 (13:28) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) Global Growth Robust, Macro Issues Ail
Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:27) / "Zacks Commentary" (by Zacks Equity Research)
PetIQ ( PETQ ) Broadens Minties Line With Large Dogs Dental Treats
PetIQ (PETQ), with a focus on affordability and natural ingredients, is well-positioned to meet the evolving needs of pet owners and continue its growth trajectory in the pet wellness market.
In Article Trend: Somewhat-Bullish
March 18, 2024 (12:23) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Buy Insulet ( PODD ) Stock Right Now
Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.
In Article Trend: Somewhat-Bullish
March 18, 2024 (12:19) / "Zacks Commentary" (by Zacks Equity Research)
Exact Sciences' ( EXAS ) BLUE-C Study Results Published in NEJM
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.
In Article Trend: Somewhat-Bullish
March 18, 2024 (12:04) / "Benzinga" (by Meg Flippin)
Monogram Orthopaedics ( NASDAQ: MGRM ) Aims To Overcome Robot Shortcomings With Its Advanced Solution - Monogram Orthopaedics ( NASDAQ:MGRM ) , Stryker ( NYSE:SYK )
When it comes to robots in the operating room, they are falling short. Robots should save hospitals time and money and give patients better outcomes, but those benefits have yet to be seen. As it stands, the current robots decrease surgical throughput, add costs, and cannot achieve parity with ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (07:14) / "Benzinga" (by Benzinga Neuro)
Which Stocks Will Dominate The Future Of Tech? UBS Shares Its Top Picks In AI, Healthtech, Greentech, And Fintech - Air Liquide ( OTC:AIQUY ) , ASML Holding ( NASDAQ:ASML )
In a recent report, global wealth manager UBS identified the sectors likely to drive the next wave of technological innovation and the stocks that stand to benefit. What Happened: UBS has pinpointed artificial intelligence ( AI ) , cybersecurity, health tech, Greentech, and fintech as the sectors ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (20:01) / "Benzinga" (by Benzinga Insights)
Stryker Unusual Options Activity - Stryker ( NYSE:SYK )
High-rolling investors have positioned themselves bearish on Stryker SYK, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
In Article Trend: Neutral
March 15, 2024 (14:50) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences ( EW ) Hits 52-Week High: What's Driving It?
Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:30) / "Zacks Commentary" (by Zacks Equity Research)
Charles River ( CRL ) Extends Gene Therapy Offering With New Pact
Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
In Article Trend: Neutral
March 15, 2024 (13:25) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp ( LH ) Expands Strategic Alliances, Test Sales Fall
Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.
In Article Trend: Somewhat-Bullish
March 14, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $8,100 Today - Stryker ( NYSE:SYK )
Stryker SYK has outperformed the market over the past 20 years by 2.97% on an annualized basis producing an average annual return of 11.01%. Currently, Stryker has a market capitalization of $134.77 billion.
In Article Trend: Somewhat-Bullish
March 14, 2024 (14:24) / "Zacks Commentary" (by Zacks Equity Research)
Envista ( NVST ) Faces Macroeconomic Challenges, FX Headwind
The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.
In Article Trend: Somewhat-Bullish
March 14, 2024 (14:16) / "Zacks Commentary" (by Zacks Equity Research)
Inspira Technologies ( IINN ) Releases Favorable Data on VORTX
Inspira Technologies' (IINN) proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:46) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Charles River ( CRL ) Stock Now
Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:08) / "Zacks Commentary" (by Zacks Equity Research)
Bruker ( BRKR ) Up 20.7% Since Last Earnings: What's Driving It?
Investors are upbeat about Bruker (BRKR) led by strong NANO group prospects and strong guidance.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Chemed's ( CHE ) VITAS Segment Inks New Deal With Covenant Care
Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.
In Article Trend: Bullish
March 13, 2024 (16:01) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Globus Medical ( GMED ) Stock Now
Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.
In Article Trend: Somewhat-Bullish
March 13, 2024 (15:57) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences' ( EW ) SAPIEN TAVR Study Outcome Favorable
Edwards Lifesciences' (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes for patients receiving SAPIEN TAVR.
In Article Trend: Somewhat-Bullish
March 13, 2024 (12:34) / "Zacks Commentary" (by Zacks Equity Research)
Alcon's ( ALC ) New Launch Strengthens IOL Innovation Leadership
Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.
In Article Trend: Somewhat-Bullish
March 13, 2024 (12:00) / "Canada Newswire" (by Foot Locker)
FOOT LOCKER, INC. NAMES CINDY CARLISLE CHIEF HUMAN RESOURCES OFFICER
Carlisle brings over 24 years of leadership experience to her role at Foot Locker, Inc. NEW YORK, March 13, 2024 /CNW/ -- Foot Locker, Inc. ( NYSE: FL ) today announced that Cindy Carlisle has assumed the role of Executive Vice President and Chief Human Resources Officer.
In Article Trend: Somewhat-Bullish
March 12, 2024 (16:04) / "Zacks Commentary" (by Zacks Equity Research)
Integra LifeSciences ( IART ) Introduces MicroMatrix Flex
Integra LifeSciences' (IART) MicroMatrix Flex has a flexible tip that delivers a flowable version of the Urinary Bladder Matrix (UBM) technology.
In Article Trend: Neutral
March 12, 2024 (12:27) / "Zacks Commentary" (by Zacks Equity Research)
Bio-Rad ( BIO ) Suffers due to BioPharma Softness, Stiff Competition
Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
In Article Trend: Neutral
March 12, 2024 (12:22) / "Zacks Commentary" (by Zacks Equity Research)
KORU Medical ( KRMD ) Forms New Deal on Subcutaneous Infusion
One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.
In Article Trend: Bullish
March 12, 2024 (12:03) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Medtronic ( MDT ) Stock for Now
Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.
In Article Trend: Somewhat-Bullish
March 12, 2024 (11:51) / "Zacks Commentary" (by Zacks Equity Research)
Bruker ( BRKR ) Announces Advanced timsTOF Solutions at US HUPO
Bruker (BRKR) advances CCS-Enabled 4D-Proteomics timsTOF solutions for immunopeptidomes and glycoproteomics at the US HUPO 2024.
In Article Trend: Somewhat-Bullish
March 11, 2024 (14:20) / "Zacks Commentary" (by Zacks Equity Research)
Thermo Fisher ( TMO ) Unveils CorEvitas Clinical Registry in GPP
Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:18) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Teleflex ( TFX ) Stock for Now
Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:17) / "Zacks Commentary" (by Zacks Equity Research)
Medtronic's ( MDT ) MiniMed 780G System Study Data Favorable
Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.
In Article Trend: Somewhat-Bullish
March 11, 2024 (12:25) / "Zacks Commentary" (by Zacks Equity Research)
Zimmer Biomet ( ZBH ) Rides on ROSA Uptake, Favorable Trend
Focused execution of Zimmer Biomet's (ZBH) global sales teams amid a stable global musculoskeletal market helps accelerate global sales.
In Article Trend: Somewhat-Bullish
March 9, 2024 (03:15) / "PR Newswire" (by Research and Markets)
Global Hospital Beds Market Insights 2024: A $4.84 Billion Industry by 2029, Driven by a Large Pool of Target Patient Population, Increasing Elderly Population, and Chronic Disease Prevalence
Global Hospital Beds Market Insights 2024: A $4.84 Billion Industry by 2029, Driven by a Large Pool of Target Patient ... PR ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (16:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Phibro ( PAHC ) Up 12.7% Since Last Earnings Report?
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 8, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Phibro ( PAHC ) Up 12.7% Since Last Earnings Report?
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 8, 2024 (15:26) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp ( LH ) Introduces Weight Loss Management Portfolio
Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.
In Article Trend: Somewhat-Bullish
March 8, 2024 (13:06) / "Zacks Commentary" (by Zacks Equity Research)
Neuronetics ( STIM ) Progresses in MRD and TRD With New Deal
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:31) / "Zacks Commentary" (by Zacks Equity Research)
Alcon's ( ALC ) Vivity EDOF IOL Achieves One Million Milestone
Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.
In Article Trend: Somewhat-Bullish
March 7, 2024 (17:28) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Walgreens Boots ( WBA ) For Now
Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.
In Article Trend: Somewhat-Bullish
March 7, 2024 (17:27) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) to Reduce Childhood Malnutrition With New Pact
Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.
In Article Trend: Somewhat-Bullish
March 7, 2024 (16:02) / "Zacks Commentary" (by Zacks Equity Research)
Phibro ( PAHC ) Appears Well Poised on Launches, Vaccine Sales
Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.
In Article Trend: Somewhat-Bullish
March 7, 2024 (12:33) / "Zacks Commentary" (by Zacks Equity Research)
ResMed ( RMD ) Debuts the Smallest Full-Face CPAP Mask AirFit F40
ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.
In Article Trend: Somewhat-Bullish
March 7, 2024 (12:29) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Hold on to Neogen ( NEOG ) Stock Now
Solid progress in long-term growth strategies bodes well for Neogen (NEOG).
In Article Trend: Bullish
March 6, 2024 (16:15) / "Zacks Commentary" (by Zacks Equity Research)
Hologic's ( HOLX ) BCI Genomic Test Study Outcome Favorable
Hologic's (HOLX) BCI test is the only genomic test that is approved by various national oncology guidelines.
In Article Trend: Neutral
March 6, 2024 (14:50) / "Zacks Commentary" (by Zacks Equity Research)
Quanterix ( QTRX ) AD Offering Gets FDA's Breakthrough Device Tag
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:43) / "Zacks Commentary" (by Zacks Equity Research)
Edwards ( EW ) Gains From RESILIA's Global Adoption, TAVR Growth
With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.
In Article Trend: Somewhat-Bullish
March 6, 2024 (13:46) / "Zacks Commentary" (by Zacks Equity Research)
Stryker ( SYK ) Completes First Arthroplasty Surgery in Europe
Stryker (SYK) completes its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.
In Article Trend: Somewhat-Bullish
March 6, 2024 (11:54) / "Zacks Commentary" (by Zacks Equity Research)
Haemonetics ( HAE ) Signs Agreement to Acquire Attune Medical
Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.
In Article Trend: Somewhat-Bullish
March 5, 2024 (17:55) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain Prestige Consumer ( PBH ) Stock for Now
Investors are optimistic about Prestige Consumer (PBH) on increasing gain in market share for its wide array of brands.
In Article Trend: Somewhat-Bullish
March 5, 2024 (17:48) / "Zacks Commentary" (by Zacks Equity Research)
CVS Health ( CVS ) Expands In-Home Diagnostic Care With New Test
CVS Health's (CVS) new launch will enable early detection of heart arrhythmia and can help mitigate symptoms and more severe complications.
In Article Trend: Somewhat-Bullish
March 5, 2024 (14:49) / "Zacks Commentary" (by Zacks Equity Research)
Penumbra ( PEN ) Gains From Innovation, Mounting Costs Ail
Penumbra (PEN) expects to materially increase both revenues and profitability in the company's international business in the next three years and beyond.
In Article Trend: Somewhat-Bullish
March 5, 2024 (13:23) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Bruker ( BRKR ) Stock Now
The strength of the BSI BioSpin and CALID groups bodes well for Bruker (BRKR).
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
QIAGEN ( QGEN ) Launches AI-Driven Biomedical Knowledge Base
QIAGEN (QGEN) introduces a Biomedical KB-AI knowledge base to accelerate data-driven drug discovery.
In Article Trend: Somewhat-Bullish
March 1, 2024 (16:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Boston Scientific ( BSX ) Up 2.1% Since Last Earnings Report?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Somewhat-Bullish
March 1, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
Peering Into Stryker's Recent Short Interest - Stryker ( NYSE:SYK )
Stryker's SYK short percent of float has fallen 12.03% since its last report. The company recently reported that it has 4.18 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.32 days to cover their ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (14:41) / "Zacks Commentary" (by Zacks Equity Research)
Myriad Genetics ( MYGN ) to Evaluate MRD Testing With New Pact
Myriad Genetics' (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential for a pan-cancer investigation.
In Article Trend: Neutral
March 1, 2024 (13:43) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Omnicell ( OMCL ) Stock Now
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.
In Article Trend: Somewhat-Bullish
February 29, 2024 (16:30) / "Benzinga" (by Globe Newswire)
Endoscopic Camera Market Size Is Expected To Grow At A Rate Of More Than 9% Through 2024-2028 As Per The Business Research Company's Endoscopic Camera Global Market Report 2024
LONDON, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Endoscopic Camera Global Market Report 2024, the endoscopic camera market has witnessed robust growth in recent years, with significant advancements in minimally invasive surgery, medical training, and patient ...
In Article Trend: Somewhat-Bullish
February 29, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
Integra's ( IART ) Q4 Earnings Miss Estimates, Margins Down
Integra's (IART) Q4 revenues are impacted by the decline in the Tissue Technologies segment.
In Article Trend: Neutral
February 29, 2024 (13:01) / "Zacks Commentary" (by Zacks Equity Research)
National Vision ( EYE ) Q4 Earnings Top Estimates, Margins Fall
National Vision's (EYE) Q4 adjusted comparable store sales growth is driven by ongoing strength within America's Best and Eyeglass World sales.
In Article Trend: Somewhat-Bullish
February 29, 2024 (11:37) / "Zacks Commentary" (by Zacks Equity Research)
Chemed ( CHE ) Q4 Earnings Surpass Estimates, Margins Expand
Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
Tactile Systems Technology, Inc. (TCMD)
Walgreens Boots Alliance, Inc. (WBA)
Aadi Bioscience, Inc. (AADI)
Zoetis Inc. (ZTS)
Rockwell Medical, Inc. (RMTI)
Petros Pharmaceuticals, Inc. (PTPI)
Antares Pharma, Inc. (ATRS)
BioXcel Therapeutics, Inc. (BTAI)
IO Biotech, Inc. (IOBT)
Nuvectis Pharma, Inc. (NVCT)
This website uses cookies to ensure you get the best experience on our website